Paper76519
The alpha2-plasmin inhibitor levels in liver diseases.
Aoki N and 1 other. Clin Chim Acta, 1978. Cited by 95 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The alpha2-plasmin inhibitor levels in liver diseases. Papers, record 76519. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/76519
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Blood Proteins | Major topic |
| Fibrinolysin | Major topic |
| Liver Diseases | Major topic |
| Adult | |
| Female | |
| Humans | |
| Liver Cirrhosis | |
| Male | |
| alpha 1-Antitrypsin | |
| alpha-Macroglobulins |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 95 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39,628,652 | Enhanced thrombin and plasmin generation profiles in alpha-2-antiplasmin-deficient patients: Data from the Rare Bleeding disorders in the Netherlands study. | Res Pract Thromb Haemost | 2024 | https://conductscience.org/library/papers/39628652 | PubMed |
| 36,452,200 | Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target. | TH Open | 2022 | https://conductscience.org/library/papers/36452200 | PubMed |
| 34,830,419 | Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34830419 | PubMed |
| 30,271,063 | Emergent Neurosurgical Management of a Rapidly Deteriorating Patient with Acute Intracranial Hemorrhage and Alcohol-Related Thrombocytopenia. | J Neurosci Rural Pract | 2018 | https://conductscience.org/library/papers/30271063 | PubMed |
| 21,415,961 | Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. | Mediterr J Hematol Infect Dis | 2009 | https://conductscience.org/library/papers/21415961 | PubMed |
| 9,038,736 | Hyperfibrinolysis in hepatosplenic schistosomiasis. | J Clin Pathol | 1996 | https://conductscience.org/library/papers/9038736 | PubMed |
| 7,199,538 | Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. | J Clin Invest | 1982 | https://conductscience.org/library/papers/7199538 | PubMed |
| 6,852,439 | Usefulness of antithrombin III and alpha 2-plasmin inhibitor in early differentiation of fulminant hepatitis and severe form of acute hepatitis. | Gastroenterol Jpn | 1983 | https://conductscience.org/library/papers/6852439 | PubMed |
| 6,479,679 | Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance. | Gut | 1984 | https://conductscience.org/library/papers/6479679 | PubMed |
| 6,444,305 | Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. | J Clin Invest | 1980 | https://conductscience.org/library/papers/6444305 | PubMed |
| 6,291,058 | Synthesis and secretion of alpha 2-plasmin inhibitor by established human liver cell lines. | Proc Natl Acad Sci U S A | 1982 | https://conductscience.org/library/papers/6291058 | PubMed |
| 6,235,248 | Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. | J Clin Pathol | 1984 | https://conductscience.org/library/papers/6235248 | PubMed |
| 6,085,504 | Profiles of acute-phase reactants and clinical significance of alpha 2-macroglobulin in acute hepatitis B. | Inflammation | 1983 | https://conductscience.org/library/papers/6085504 | PubMed |
| 3,493,701 | Extravascular plasminogen activator and inhibitor activities detected at the site of a chronic mycobacterial-induced inflammation. | Am J Pathol | 1987 | https://conductscience.org/library/papers/3493701 | PubMed |
| 3,296,855 | Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation. | Anesthesiology | 1987 | https://conductscience.org/library/papers/3296855 | PubMed |
| 2,526,671 | Clinical disorders of fibrinolysis: a critical review. | Blut | 1989 | https://conductscience.org/library/papers/2526671 | PubMed |
| 156,196 | Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. | J Clin Invest | 1979 | https://conductscience.org/library/papers/156196 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| A2M | 2 | PubTator's text mining | https://conductscience.org/library/genes/2 | NCBI Gene |
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| BCHE | 590 | PubTator's text mining | https://conductscience.org/library/genes/590 | NCBI Gene |
| PLG | 5,340 | PubTator's text mining | https://conductscience.org/library/genes/5340 | NCBI Gene |
| SERPINA1 | 5,265 | PubTator's text mining | https://conductscience.org/library/genes/5265 | NCBI Gene |
| SERPINF2 | 5,345 | PubTator's text mining | https://conductscience.org/library/genes/5345 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/76519
GET https://conductscience.org/api/papers/v1/76519/authors